NO20021834L - Orale formuleringer av anti-tumorforbindelser - Google Patents

Orale formuleringer av anti-tumorforbindelser

Info

Publication number
NO20021834L
NO20021834L NO20021834A NO20021834A NO20021834L NO 20021834 L NO20021834 L NO 20021834L NO 20021834 A NO20021834 A NO 20021834A NO 20021834 A NO20021834 A NO 20021834A NO 20021834 L NO20021834 L NO 20021834L
Authority
NO
Norway
Prior art keywords
oral formulations
tumor compounds
tumor
compounds
formulations
Prior art date
Application number
NO20021834A
Other languages
English (en)
Other versions
NO322782B1 (no
NO20021834D0 (no
Inventor
Lorena Mugetti
Alessandro Martini
Paolo Civaroli
Christopher James
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of NO20021834L publication Critical patent/NO20021834L/no
Publication of NO20021834D0 publication Critical patent/NO20021834D0/no
Publication of NO322782B1 publication Critical patent/NO322782B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20021834A 1999-10-22 2002-04-18 Farmasoytisk sammensetning og oral formulering omfattende et kamptotekinderivat samt fremgangsmate for fremstilling av samme NO322782B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9925127.4A GB9925127D0 (en) 1999-10-22 1999-10-22 Oral formulations for anti-tumor compounds
PCT/EP2000/009647 WO2001030351A1 (en) 1999-10-22 2000-10-02 Oral formulations for anti-tumor compounds

Publications (3)

Publication Number Publication Date
NO20021834L true NO20021834L (no) 2002-04-18
NO20021834D0 NO20021834D0 (no) 2002-04-18
NO322782B1 NO322782B1 (no) 2006-12-11

Family

ID=10863264

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20021834A NO322782B1 (no) 1999-10-22 2002-04-18 Farmasoytisk sammensetning og oral formulering omfattende et kamptotekinderivat samt fremgangsmate for fremstilling av samme

Country Status (26)

Country Link
US (1) US7201913B1 (no)
EP (1) EP1223936A1 (no)
JP (1) JP2003512430A (no)
KR (1) KR100838097B1 (no)
CN (1) CN1198616C (no)
AR (1) AR031834A1 (no)
AU (1) AU784201B2 (no)
BR (1) BR0014902A (no)
CA (1) CA2387648A1 (no)
CO (1) CO5251471A1 (no)
CZ (1) CZ20021372A3 (no)
EA (1) EA008284B1 (no)
GB (1) GB9925127D0 (no)
HK (1) HK1048253B (no)
HU (1) HUP0202850A3 (no)
IL (2) IL149044A0 (no)
MX (1) MXPA02003904A (no)
MY (1) MY138106A (no)
NO (1) NO322782B1 (no)
NZ (1) NZ518398A (no)
PE (1) PE20010809A1 (no)
PL (1) PL356236A1 (no)
SK (1) SK5102002A3 (no)
TW (1) TWI233355B (no)
WO (1) WO2001030351A1 (no)
ZA (1) ZA200203042B (no)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE200200471A (et) * 2000-02-28 2003-12-15 Aventis Pharma S.A. Farmatseutiline kompositsioon, mis sisaldab kamptotetsiini või selle derivaati kombinatsioonis pürimidiini derivaadiga ning on ette nähtud vähktõve raviks
GB0011903D0 (en) * 2000-05-18 2000-07-05 Astrazeneca Ab Combination chemotherapy
ITRM20030074A1 (it) * 2003-02-21 2004-08-22 Pharmacia Italia Spa Formulazioni semisolide a rilascio immediato intese
US7871632B2 (en) 2004-07-12 2011-01-18 Adventrx Pharmaceuticals, Inc. Compositions for delivering highly water soluble drugs
GT200500310A (es) 2004-11-19 2006-06-19 Compuestos organicos
SA06270147B1 (ar) 2005-06-09 2009-12-22 نوفارتيس ايه جي عملية لتخليق 5-(مثيل–1h–إيميدازول–1-يل )–3-(ثلاثي فلـورو مثيل)–بنزامـين
US20070053869A1 (en) * 2005-09-02 2007-03-08 Yuichi Sugiyama Formulation and method for enhancement of gastrointestinal absorption of pharmaceutical agents
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
DK2116241T3 (en) 2007-01-26 2016-06-06 Pola Pharma Inc pharmaceutical composition
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
US20100310661A1 (en) * 2007-07-16 2010-12-09 Poniard Pharmaceuticals, Inc. Oral formulations for picoplatin
AU2009210734A1 (en) * 2008-02-08 2009-08-13 Poniard Pharmaceuticals, Inc. Picoplatin and amrubicin to treat lung cancer
HUP0900614A2 (en) * 2009-09-29 2011-05-30 Mate Dr Hidvegi Preparation comprising dehydrated, fermented material with amorphous crystaline structure and process for its production
US20120322752A1 (en) * 2009-12-08 2012-12-20 Sung Kyun Lee SOLID DISPERSIONS CONTAINING 20-O-beta-D-GLUCOPYRANOSYL-20(S)-PROTOPANAXADIOL
MX2015010041A (es) 2013-02-05 2015-10-30 Purdue Pharma Lp Formulacion farmaceuticas resistentes a la alteracion.
US10143657B2 (en) 2014-01-17 2018-12-04 Oncoral Pharma Aps Solid oral dosage form of irinotecan for the treatment of cancer
CN110448533B (zh) * 2014-12-05 2022-03-29 天津键凯科技有限公司 一种聚乙二醇修饰的喜树碱类衍生物的药物组合物及其制备方法
KR102293907B1 (ko) 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
KR102066402B1 (ko) * 2017-12-22 2020-01-15 대화제약 주식회사 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물
KR102185475B1 (ko) 2019-06-20 2020-12-02 대화제약 주식회사 이리노테칸 자유 염기를 포함하는 경구투여용 약학 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA909847B (en) * 1989-12-13 1992-08-26 Lilly Co Eli Glycopeptide derivatives
US5552156A (en) 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
US5433951A (en) 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
IL115099A (en) 1994-10-14 1999-04-11 Upjohn Co Lyophilizate of phospholipid complex of water insoluble camptothecins
IL116674A (en) * 1995-01-09 2003-05-29 Mendell Co Inc Edward Microcrystalline cellulose-based excipient having improved compressibility, pharmaceutical compositions containing the same and methods for the preparation of said excipient and of solid dosage form thereof
US5954998A (en) * 1995-05-25 1999-09-21 The Clorox Company Liquid peracid precursor colloidal dispersions: oil-core vesicles
WO1998038984A2 (en) * 1997-03-05 1998-09-11 Sugen, Inc. Formulations for hydrophobic pharmaceutical agents
GB9711962D0 (en) * 1997-06-10 1997-08-06 Reckitt & Colmann Prod Ltd Therapeutically active compositions
ES2174462T3 (es) * 1997-07-29 2002-11-01 Upjohn Co Formulacion autoestimulante para compuestos lipofilos.
AR013261A1 (es) * 1997-08-01 2000-12-13 Smithkline Beecham Corp Formulaciones farmaceuticas para analogos de camptotecina en capsula de gelatina
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
CA2373931A1 (en) * 1999-05-17 2000-11-23 Richard Love Dfmo and celecoxib in combination for cancer chemoprevention and therapy
GB9918885D0 (en) * 1999-08-10 1999-10-13 Pharmacia & Upjohn Spa Pharmaceutical formulations in hydroxypropymethycellulose capsules

Also Published As

Publication number Publication date
CA2387648A1 (en) 2001-05-03
MXPA02003904A (es) 2003-07-14
NZ518398A (en) 2004-01-30
TWI233355B (en) 2005-06-01
AU7661300A (en) 2001-05-08
GB9925127D0 (en) 1999-12-22
MY138106A (en) 2009-04-30
BR0014902A (pt) 2002-06-11
EA008284B1 (ru) 2007-04-27
PE20010809A1 (es) 2001-08-01
KR100838097B1 (ko) 2008-06-13
EP1223936A1 (en) 2002-07-24
IL149044A0 (en) 2002-11-10
SK5102002A3 (en) 2002-11-06
HK1048253B (zh) 2005-12-02
NO322782B1 (no) 2006-12-11
EA200200480A1 (ru) 2002-10-31
HK1048253A1 (en) 2003-03-28
AR031834A1 (es) 2003-10-08
AU784201B2 (en) 2006-02-23
NO20021834D0 (no) 2002-04-18
CN1198616C (zh) 2005-04-27
HUP0202850A2 (hu) 2003-01-28
CO5251471A1 (es) 2003-02-28
US7201913B1 (en) 2007-04-10
PL356236A1 (en) 2004-06-28
CN1382050A (zh) 2002-11-27
CZ20021372A3 (cs) 2002-09-11
JP2003512430A (ja) 2003-04-02
IL149044A (en) 2007-03-08
WO2001030351A1 (en) 2001-05-03
ZA200203042B (en) 2003-04-17
HUP0202850A3 (en) 2004-12-28
KR20020045613A (ko) 2002-06-19

Similar Documents

Publication Publication Date Title
NO20021834D0 (no) Orale formuleringer av anti-tumorforbindelser
AR026045A1 (es) Formulaciones de liberacion prolongada de derivados de eritromocina
NO994946D0 (no) Formuleringer med forlenget frigivelse av erytromycinderivater
DE122008000001I1 (de) Orale Dosiszusammensetzungen mit verlängerter Freigabe
IS2325B (is) Örgerðar samsetningar epleróns
NO20015536D0 (no) FAP-aktiverte anti-tumor-forbindelser
NO962490D0 (no) Orale formuleringer av S(+)-ibuprofen
DE60218175D1 (de) Stabilisierte orale suspensionsformulierung
NO20020185L (no) Formuleringer av IL-11
ATE259590T1 (de) Pour-on formulierungen
NO993096D0 (no) Orale cyklosporinformuleringer
NO962491D0 (no) Orale formuleringer av S(+)-etodolac
NO20001585D0 (no) Orale sammensetninger av levosimendan
ITMI991826A0 (it) Nuova formulazione orale
NO20021860L (no) Formulering av substituerte benzimidazoler
NO20016151D0 (no) Fremstilling av substituerte piperidin-4-oner
DK1216032T3 (da) Orale formuleringer med kontrolleret frigivelse
NO996044L (no) Rapamycinformuleringer for oral administrasjon
EE04220B1 (et) Kontrollitud vabanemisega levosimendani peroraalsed koostised
EE200200213A (et) Suukaudselt manustatav galantamiinilahus
NO20003799L (no) Innkorporering av kolesterol senkende midler i konfekt- dosisformer
NO20014845D0 (no) Anvendelse av arylalkanoylpyridaziner
NO20016030L (no) Derivater av 4'-demykarosyl-8a-aza-8a-homotylosin
NO20022446D0 (no) Etere av O-desmetyl-venlafaxine
NO20035668D0 (no) Antitumorformuleringer av tioxantenon